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Abstract: X-linked dystonia–parkinsonism (XDP; OMIM314250), also referred to as DYT3 dystonia or
“Lubag” disease, was first described as an endemic disease in the Philippine island of Panay. XDP is
an adult-onset movement disorder characterized by progressive and severe dystonia followed by
overt parkinsonism in the later years of life. Among the primary monogenic dystonias, XDP has
been identified as a transcriptional dysregulation syndrome with impaired expression of the TAF1
(TATA box-binding protein associated factor 1) gene, which is a critical component of the cellular
transcription machinery. The major neuropathology of XDP is progressive neuronal loss in the
neostriatum (i.e., the caudate nucleus and putamen). XDP may be used as a human disease
model to elucidate the pathomechanisms by which striatal neurodegeneration leads to dystonia
symptoms. In this article, we introduce recent advances in the understanding of the interplay between
pathophysiology and genetics in XDP.
Keywords: X-linked dystonia–parkinsonism; striatum; striosome; neurodegeneration; genetics;
pathophysiology
1. Introduction
X-linked dystonia–parkinsonism (XDP; OMIM314250), also known as DYT3 dystonia or “Lubag”
disease, is a hereditary neurodegenerative disorder that primarily involves the striatum. XDP may be
a unique human disease model used to investigate the pathogeneses of dystonia and parkinsonism.
It was first described as an endemic disease on the island of Panay in the Philippines [1]. XDP is
now classified as a primary monogenic torsion dystonia [2]. This adult-onset movement disorder
is clinically characterized by progressive and severe dystonia, followed by overt parkinsonism in
the later years of life [3]. Like Huntington’s disease (HD) and spinocerebellar ataxia 17 (SCA17),
XDP has been identified as a transcriptional dysregulation syndrome [4]. XDP involves the impaired
expression of the TAF1 (TATA box-binding protein associated factor 1) gene [5], which is ubiquitously
expressed and is an essential component of the transcription machinery [6]. The major neuropathology
of XDP is progressive neuronal loss in the neostriatum (i.e., the putamen and caudate nucleus) [7–9],
where compartmental and cell type-specific degeneration of striatal neurons is found [8,9]. Among
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the primary monogenic dystonias, XDP is a unique heredodegenerative disorder whose causative
gene and functional pathology have been explicated. Here, we introduce recent advances in the
understanding of the genetic and clinicopathological features of XDP.
2. Clinical Phenotype
XDP is originally endemic to the island of Panay in the Philippines [1]. As of 2001, its prevalence
rate for the entire Philippines was 0.31 per 100,000, although it was as high as 5.24 per 100,000 in
the island of Panay [10]. Currently, affected Filipinos with XDP are also found in the USA, Canada,
Germany, UK, and Japan [3,11].
The striking clinical feature in patients with XDP is the contradictory biphasic movement disorder
manifestation, namely dystonia and parkinsonism. The onset of the disease usually occurs in the
late 30s to early 40s (mean, 39.67; range, 12–64) [3]. It usually starts with focal dystonia (94.3%),
although some patients first present with parkinsonism (5.7%) [3]. On average, focal dystonia becomes
generalized within four years (range, 1–23 years), and most patients (84%) present with generalized
dystonia within five years of disease onset [3]. Eventually, the vast majority of patients with focal
dystonia (97%) develop generalized dystonia [3]. Generalized dystonia affects the craniofacial and
cervical segments, the upper and lower limbs, and the trunk [3,10]. Dystonia is typically predominant
until the seventh year of illness. Parkinsonism becomes gradually more prominent between the
seventh and 10th year after onset [11]. The mean duration from onset to predominant parkinsonism is
14 years (range, 7–25) years [3]. To date, 14 affected female patients have been reported, while more
than 500 men have been diagnosed with XDP [12]. Homozygosity and skewed X-inactivation can
lead to XDP in women [5,12]. Female XDP carriers are mostly asymptomatic and symptomatic female
carriers usually manifest non-progressive focal dystonia, chorea, focal tremor, or non-progressive mild
parkinsonism [12–14]. Pain is frequently observed in 80% of individuals with oromandibular dystonia
and in 75% of those with truncal–axial dystonia due largely to muscle contraction [15].
Cognitive impairment in patients with XDP is usually mild. However, 76% of patients with XDP
fail one of the following tests: the Mini-Mental State Examination, the Clock Drawing Test, and Frontal
Assessment Battery [16]. There may be impairments in the dorsolateral frontal lobe functions of
abstract thinking and conceptualization [16]. Executive dysfunction has been noted in three case
reports [17–19]. Using a flanker task, a set of response inhibition tests used to assess the ability to
inhibit inappropriate responses in a particular context, Beste et al. [20] have reported that error-related
behavioral adaptation is markedly impaired in patients with XDP in the early disease stages. Abnormal
error processing is correlated with dystonia severity, but not with parkinsonism [20]. Interestingly,
response inhibition in a go/no-go task and corresponding electroencephalograms are normal in
patients with XDP [20]. This indicates a lack of impulsivity. The authors concluded that dysfunction
in behavioral adaptation might reflect striosomal dysfunction [20]. The same group reported faster
and more accurate perceptual decision-making performance in predictive coding processes using
distracting pitches of tones in patients with XDP when compared to healthy controls [21]. Predictive
coding is the ability to predict upcoming events on the basis of extracted regularities of previous
inputs, and is known to depend on fronto-striatal circuits [22]. There was less response slowing and a
smaller reduction of accuracy when XDP patients, in their early dystonic stages, were confronted with
the distracting pitches of the tones compared to controls [21]. These results suggested that striosomal
dysfunction was associated with this paradoxical benefit for perceptual decision-making processes [21].
The authors hypothesized that striosomal dysfunction in XDP patients reduced its interferences to the
matrix, which might result in better perceptual decision-making processes [21].
The mean age of death in patients with XDP is 55.59 (range, 31–81) years. Death usually occurs
due to malnutrition or aspiration pneumonia [3,11]. Causes of death include a non-ignorable number
of suicides (9%) [3]. Notably, 14.3% of patients with XDP have major depression, according to the
Diagnostic and Statistical Manual-IV (DSM-IV) criteria [23]. In addition, 35.7% of patients with XDP
have anxiety disorders, including social phobia (28.6%), agoraphobia (21.4%), and panic disorder
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(7.1%), as determined using the DSM-IV [23]. Depressive symptoms are highly prevalent in up to
92.9% of patients, as determined using the Zung Self-Rating Depression Scale, and in 54.8% of patients
when they are assessed using the Hamilton Depression Rating Scale (HAM-D) [16,23]. A worsening of
both Burke–Fahn–Marsden Dystonia Rating Scale (BFM-DRS) and Schwab and England Activities
of Daily Living scores are significantly correlated with positive HAM-D scores [16]. The functional
impairment caused by severe dystonia or end-stage parkinsonism usually induces severe disability in
activities of daily living (ADL) [3]. Thus, both the neuropathological changes in the central nervous
system and disability in ADL may affect mood in patients with XDP, which might explain the high
rate of suicide.
3. Neuroimaging
A review of magnetic resonance imaging films from 46 patients with XDP by Pasco et al. indicated
six of the patients had normal findings, while 40 had abnormal findings [24]. All six films without
abnormal findings were imaged during the early dystonic phase. All of the 40 films with abnormal
findings contained hyperintense putaminal rims and 72% displayed atrophy of the caudate head.
Putaminal atrophy was found in 30% of the films, which were imaged mostly during the later
parkinsonism stage.
Severe bilateral putaminal metabolic deficits assessed using [18F] fluorodeoxyglucose positron
emission tomography (PET) have been reported from the early to late stages of XDP [7,25,26]. Using
[18F] fluorodopa, normal and reduced dopamine re-uptake by presynaptic terminals have been
observed in patients with the early dystonic stage and the moderately severe parkinsonism stage,
respectively [7,25,26].
Dopamine transporter imaging using [123I] β-carbomethoxy-iodophenyl-nortropane and [123I]
fluoropropyl-2-beta-carbomethoxy-3-beta(4-iodophenyl) nortropane single-photon emission computed
tomography (SPECT) studies show moderately reduced uptake in the bilateral putamen in patients
with XDP in the early to middle stages of the disease [14,27,28]. There is an inconsistency between
PET and SPECT studies related to presynaptic dopaminergic function in XDP patients in the early
dystonia phase. While [18F] fluorodopa PET studies showed normal presynaptic dopaminergic
terminal innervation, dopamine transporter imaging SPECT studies demonstrated reduced presynaptic
dopaminergic afferents [7,25–28]. Dopamine D2 receptor (D2R) imaging using [123I] iodobenzamide
(IBZM)-SPECT indicates a slight to moderate decrease in D2R expression in the bilateral striatum
in patients with XDP in the early to middle stages of disease [27,28]. Longer disease duration
is correlated with lower IBZM-binding ratios in the right striatum [28]. However, IBZM-SPECT
cannot distinguish pre-synaptic D2R from post-synaptic D2R, thus it cannot be judged whether
IBZM-SPECT reduction reflects striatal neuron loss or the loss of D2R-positive afferents [29]. It is
difficult to derive any definitive conclusion from these studies due to small sample size. Walter et
al. enrolled 90 Filipino participants in a brain sonography study [30]. They reported presynaptic
alteration in XDP patients with prominent parkinsonism by showing a positive correlation between
hyperechogenicity in substantia nigra and the severity of parkinsonism. On the other hand, there was
a negative correlation between hyperechogenicity in substantia nigra and the severity of dystonia.
A majority of XDP patients present pure dystonia or a dystonia-predominant phenotype from the
early stages, suggestive of a predominant involvement of postsynaptic dysfunction [14]. Few XDP
patients represent pure parkinsonism, with a subsequent manifestation of dystonia in later stages or a
parkinsonism-predominant phenotype from the early stages suggestive of a predominant involvement
of presynaptic defect [14]. XDP-related genetic changes may underlie the genesis of these different
phenotypes [14,30].
4. Treatments
A variety of pharmacological and surgical therapies have been proposed for the treatment
of dystonia and parkinsonism in patients with XDP. Oral medications such as benzodiazepines,
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anticholinergic agents, antipsychotic agents, and anti-parkinsonian medications have failed to show
convincing benefit [11]. Zolpidem and tetrabenazine might be effective for some individuals
with advanced dystonia [14,31,32]. Levodopa and dopamine agonists might have some beneficial
effects, particularly in individuals with pure parkinsonism [14]. Long-term treatment with
L-3-(3,4-Dihydroxyphenyl)alanine (L-DOPA) does not induce L-DOPA-induced dyskinesia [14].
Chemodenervation using muscle afferent block and botulinum toxin type A (BoNT-A) have
been used in patients with XDP, especially during the focal, multifocal, and segmental stages of
dystonia [11,15]. It was also noted that in 109 patients with XDP, BoNT-A injections produced
significant improvements in oromandibular, lingual, and truncal-axial dystonias, with a marked
reduction in associated pain [15].
Deep brain stimulation of the globus pallidus internus (GPi-DBS) has been used in several patients
with XDP and severe generalized dystonia [18,33–39]. The effects of bilateral GPi-DBS are always
immediate and striking [38] and lead to a 34–95% improvement in dystonia symptoms, as determined
using BFM-DRS [18,33–39]. In general, GPi-DBS may have beneficial effects on dystonia symptoms
in patients with XDP, but not on parkinsonian symptoms [35]. Notably, a study using intraoperative
pallidal microdialysis suggested that GPi-DBS might suppress dystonia symptoms by enhancing local
gamma-aminobutyric acid (GABA) release in the GPi [39]. Another study of intraoperative local field
potentials also provides evidence suggesting that GPi-DBS might improve dystonia symptoms by
suppressing beta hypersynchrony in the GPi [37].
5. Genetics
Previous conventional linkage and association studies based on linkage disequilibrium have
demonstrated that the XDP locus is within a 427 kb genetic interval on chromosome Xq13.1 [40]
(Figure 1A). This region was recently further refined to 294 kb using whole genome sequencing [5].
The refined XDP haplotype includes four known genes: TAF1, OGT, ACRC, and CXCR3 (Figure 1B).
Seven nucleotide variants have been identified within the XDP haplotype: five disease-specific
single-nucleotide changes (designated as Disease-specific Sequence Changes [DSC] 1, 2, 3, 10, and 12),
one 48 bp deletion, and one 2627 bp SVA (SINE-VNTR-Alu element) retrotransposon insertion
(Figure 1C). These variants are in complete linkage disequilibrium and no recombination events
have been detected between the variants in 21 patients with XDP [5]. The variants are located
either within the intronic region of TAF1 or in a nonconventional exon, and the intronic region at
the multiple transcript system mapped downstream of TAF1. Bioinformatics analysis indicated no
supportive evidence that these variants are located within or near potential regulatory sequences.
Copy number variants (CNVs) were investigated using whole-genome microarray analysis, but no
disease-associated CNVs were detected in the candidate region for XDP [5]. Clinical and geographical
analyses suggest that the disease-causing genetic defect is derived from a founder born in Panay
Island in the Philippines, in whom a single de novo genetic defect occurred [41]. Because it is unlikely
that two or more disease-associated variants will occur simultaneously in a single individual, one of
the seven variants is most likely the cause of XDP pathology, whereas the other variants are simply
linked changes that occurred on the same funder chromosome. Amplification of the inserted SVA
variant using a long-range polymerase chain reaction has been used for genetic testing for XDP and
has contributed to nationwide surveillance on XDP in the Philippines [42,43].
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Fig re 1. - t l c s, ca i t genes, geno ic
orga i ti , i t position of nucleotide variants, and TAF1 transcript reduced
in an XDP patient. (A) Diagram of human X chromosome. The XDP locus s t the
c r s l r i . t t l ar of the X chro oso e; ( ) Physical a genetic a at
t e X P locus. le e e se e ci a li a e ise ili ri a al sis arr e t e
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protein associated factor 1 (TAF1), O-linked N-acetylglucosa ine ( lc c) transferase ( T), acidic
repeat-containing protein (ACRC), and C-X-C otif che okine receptor 3 (CXCR3); (C) enetic
organization of TAF1 and the approximate position of seven nucleotide variants. DSC, Disease-specific
Single-nucleotide Changes; SVA, Short interspersed nuclear element; MTS, Multiple Transcript System.
The variable number of tandem repeats, and Alu composite; del48, 48 bp deletion variant. Solid
rectangles filled with black, TAF1 exons; Solid rectangles filled with blue, MTS exons. (D) Exon
structure of the human TAF1 cDNA. Positions of the start codon (ATG) and stop codon (TGA) are
indicated. The size of the full-length coding region is described in the parenthesis. bp: base pairs.
Neuron specific TAF1 transcript (N-TAF1) contains a full-length sequence derived from TAF1 exons
and a sequence of six additional bp, named exon 34’ [44], is expressed exclusively in neurons, and is the
second most abundant among all TAF1 species. A previous study demonstrated a marked reduction of
N-TAF1 in caudate in a postmortem XDP brain [45].
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Although the exact disease-causing genetic variant remains to be elucidated, decreased expression
levels of specific TAF1 transcripts have been demonstrated in postmortem brain, blood, and fibroblasts
obtained from patients with XDP [45,46]. This phenomenon was verified in induced pluripotent stem
cell (iPSC)-derived neural stem cells (NSCs), suggesting that an aberrant transcription of TAF1 occurs in
neuronal cells at the early stages of development [47]. Moreover, TAF1 dysfunction at the transcriptome
level was also shown in peripheral biomaterials where 307 genes were dysregulated. A reduction of
TAF1 transcription would impair its biological role as an RNA polymerase II-dependent transcription
factor, probably leading to the dysfunction of canonical genes, including synaptotagmin-like 2
(SYTL2) and solute carrier family 5 (inositol transporter), member 3 (SLC5A3) [46]. The gene SYTL2
plays a biological role in membrane trafficking in peripheral secretory cells through interaction
with RAS-associated protein 27A (RAB27A). The possible involvement of vesicle trafficking and
synaptogenesis in XDP pathology was previously demonstrated in cultured cells expressing specific
TAF1 isoforms containing multiple transcript system (MTS) exons d3 and d4 [48]. SLC5A3 regulates
brain osmoregulation including inositol metabolism, which is impaired in the striatum in Huntington’s
disease as well as cellular and animal models of the disease [49]. TAF1 dysfunction and neurological
disorder has also been demonstrated in another distinctive disease. Hemizygous missense and
splice-site TAF1 variants, and duplication involving TAF1, are associated with X-linked syndromic
mental retardation 33 (OMIM 300966), which is a severe neurodevelopmental disorder and has dystonic
features [50].
Considering the possible pathomechanisms caused by the reduced expression of specific TAF1
transcripts, the SVA variant is in a position to lead to genetic predisposition to XDP. The SVA variant is
inserted at intron 32 of TAF1, and might affect the expression of TAF1 transcripts. Intriguingly, an SVA
insertion has been reported to be active in the human genome and may cause disease in humans [51].
To date, two other diseases have been described wherein an SVA insertion is associated with a loss
of mRNA expression: autosomal recessive hypercholesterolemia [52] and Fukuyama-type muscular
dystrophy [53]. Genome editing technology [54] might provide more direct clues to help us determine
the exact variant affecting TAF1 transcription and function in iPSC-derived NSCs.
6. Functional Pathology
Progressive neuronal loss with replacing astrogliosis in the neostriatum (i.e., putamen and caudate
nucleus) has so far been identified as the primary neuropathology of XDP [8,9]. Postmortem studies
on patients with XDP have shown a clear correlation between clinical manifestation and striatal
pathology [8,9]. As a clinical sign, dystonia is the leading symptom in the early disease stage
(“dystonia” stage), but is associated with or replaced by parkinsonism in the later years of life
(“parkinsonism” stage) [3]. As shown in Figure 2, at the “dystonia” stage (Figure 2B,D), striatal
pathology is characterized by a compartmental loss of medium spiny neurons (MSNs) in the dorsal
striatum, where the striosome compartment is severely depleted but the matrix compartment is
relatively spared [8,9]. This compartment-specific loss of MSNs results in a striatal mosaic composed
of multiple patches of remaining matrix MSNs. These findings raise the possibility that dystonia is a
feature indicative of striosomal dysfunction. In addition, eventual loss of the direct pathway neurons
also may cause hyperkinetic symptoms in XDP. In contrast, in the parkinsonian phase (Figure 2C),
there is a greater loss of MSNs in both the striosome and matrix compartments, which leads to a
marked reduction in the interactions of their fibers with the globus pallidus and other extrastriatal
brain regions [8,55]. There is a sparing of cholinergic striatal interneurons and a significant loss of cells
positive for neuropeptide Y (NPY) in patients with XDP [8,9].
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Striosomal MSNs send their GABAergic projections directly to the substantia nigra pars compacta
(SNc), which contains dopamine-producing cells (DA-cells) that project back to both the striosome
and matrix compartments [56,57]. Thus, the striosome compartment is in a position to exert global
control over dopamine signaling in the striatum. The striosome compartment is also thought to
communicate with the matrix compartment via striatal local-circuit interneurons [56–58]. Among these
interneurons, cholinergic cells are particularly interesting, as they can control dopamine release and
their dysfunction is thought to be involved in the genesis of dystonia [59]. Moreover, a computational
model of the cortico-basal ganglia circuit has shown that the striosome compartment plays a critical
role in modular reinforcement learning [60], which could participate in the brain function of motor
“selection” or “focusing”. Based on the functional model of basal ganglia in XDP [8], we hypothesize
that at the earlier “dystonia” stage, the severe loss of the striosomal pathway leads to disinhibition
of DA-cells in the SNc, thereby increasing the action of striatal dopamine on the remaining matrix
MSNs (see Figure 3). This might result in overactivation of the basal ganglia-thalamocortical circuit,
which leads to the hyperkinetic symptoms of dystonia. A neurophysiological study [20] has shown that
the dysfunction of interconnections between the anterior cingulate cortex and the striatum, which are
known to favor the striosome compartment, might affect error-related behavioral adaptation in XDP
patients with dystonia.
Our assumption that an increase in dopaminergic activation in the remaining MSNs might occur in
the striatum in XDP is supported by the PET finding that patients with XDP and generalized dystonia
have striatal rate constants for [18F] fluorodopa uptake that are in the normal range [25] despite,
as shown here, a severe loss of striatal cells. At the later “parkinsonism” stage, the greater involvement
of the matrix compartment leads to a severe and critical reduction in matrix-based projections and
thus to the development of a so-called “extranigral form” of parkinsonism. This condition has also
been suggested in the late (or end) stage of HD [61]. Nuclear imaging studies have also suggested that
parkinsonism in XDP might result from post-synaptic striatal dysfunction [28].
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7. Pathogenesis of Striatal Neurodegeneration
The cellular and molecular processes that lead to the neurodegeneration that occurs selectively in
the neostriatum at maturity in XDP have not been elucidated to date. The gene TAF1 is ubiquitously
expressed and is an essential component of the multi-subunit transcription factor IID (TFIID) complex,
which is involved in transcription initiation by RNA polymerase II [6]. As TFIID plays a critical role
in general transcription in living cells, it is thought that the disruption of TAF1 function potentially
has broad effects on gene expression. An XDP-specific haplotype has been identified as consisting of
seven sequence variants clustering around the human TAF1 gene [4,45,46]. These variants include five
single nucleotide substitutions designated DSC 1, 2, 3, 10, and 12, a 48 bp deletion, and an SVA-type
retrotransposon insertion. A direct or specific link between these variants and disease pathogenesis has
not been clarified, and there seems to be a diversity of molecular and cellular factors that contribute to
the striatal pathology in XDP, as has also been suggested in HD [62].
Domingo et al. [46] used peripheral models of XDP (i.e., blood and fibroblasts) to show that
consistent dysregulation of common TAF1 transcripts was often accompanied by altered genome-wide
gene expression, along with an enrichment of genes and networks related to transcriptional processes.
Given the possible link between XDP-specific genetic alterations and the dysfunction of a canonical
gene, the authors suggested that TAF1 dysregulation may drive changes in gene expression in the
brains of XDP-affected individuals. Given that nuclear factor-kappa B (NFκB) signaling is present
in both fibroblasts and neural stem cells from patients with XDP, Vaine et al. [63] suggested that the
transcription pathway of NFκB may be a site of dysfunction in XDP. Herzfeld et al. [48] described a
pathological role for DSC3 in XDP because DSC3 is located within exon d4 of the TAF1/DYT3 multiple
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transcript system, even though other sequence changes are intronic. Using neuroblastoma cells,
the authors showed an effect of DSC3 on broad gene expression accompanied by an enrichment of
genes related to vesicle and synaptic function, dopamine metabolism, Ca2+ metabolism, and protection
against oxidative stress. We have suggested that the neostriatal pathology in XDP might be associated
with the impaired expression of NPY [9], which is a novel bioactive substance with a role in the
modulation of neurogenesis and neurotransmitter release, and thereby exerts a protective influence
against neurodegeneration [64]. We performed a postmortem analysis to determine the striatal
localization profile of NPY in normal individuals and in patients with XDP [9]. In normal controls,
we found a scattered distribution of NPY-positive neurons and numerous nerve fibers labeled for NPY
in the striatum, where there was a differential localization of NPY immunoreactivity in the striatal
compartments, and a heightened density of NPY labeling in the matrix compartment relative to the
striosomes [9]. In patients with XDP, there was a significant decrease in the number of NPY-positive
cells accompanied by a marked loss of their nerve fibers in the neostriatum, and a lack of NPY labeling
in the subventricular zone with a marked loss of progenitor cells [9]. These findings suggest the
presence of a neostriatal defect in the NPY system in patients with XDP. Therefore, the NPY system
may be implicated in the mechanism by which a compartmental loss of striatal neurons progressively
occurs in XDP.
8. Conclusions
XDP typically affects adult male Filipinos whose ancestries originate from the Philippine island
of Panay. XDP is unique among movement disorders, as it leads to progressive and severe dystonia in
the earlier disease stages, which are followed by overt parkinsonism in the later stages. In accordance
with this clinical course, postmortem neuropathological analyses have shown that striatal neurons
progressively degenerate in a cell-type and compartment-specific manner. Genetic analyses have
shown that XDP is a transcriptional dysregulation syndrome caused by impaired expression of the TAF1
gene. An XDP-specific haplotype has been identified and consists of seven sequence variants clustering
around the human TAF1 gene, although a direct link of these variants with disease pathogenesis has not
yet been established. In addition to striatal deregulation of dopamine transmission, multiple molecular
and cellular factors have been suggested to contribute to the development of striatal symptomatology
and pathology in XDP, similar to what has so far been described in HD [65]. A further study on the
specific link between the DYT3-specific impairment of the TAF1 gene and striatal cell vulnerability
would be required to determine the precise pathomechanism by which progressive neurodegeneration
occurs selectively in the neostriatum at maturity in XDP.
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